

# Benigno Rodriguez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2268308/publications.pdf>

Version: 2024-02-01

147  
papers

15,197  
citations

34105

52  
h-index

18130

120  
g-index

148  
all docs

148  
docs citations

148  
times ranked

14563  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut-derived bacterial toxins impair memory CD4+ T cell mitochondrial function in HIV-1 infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	13
2	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005â€“2015. <i>Journal of Infectious Diseases</i> , 2021, 223, 2113-2123.	4.0	12
3	Markers of T Cell Exhaustion and Senescence and Their Relationship to Plasma TGF-Î² Levels in Treated HIV+ Immune Non-responders. <i>Frontiers in Immunology</i> , 2021, 12, 638010.	4.8	14
4	Translocated microbiome composition determines immunological outcome in treated HIV infection. <i>Cell</i> , 2021, 184, 3899-3914.e16.	28.9	35
5	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e2334-e2337.	5.8	8
6	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>Journal of Infectious Diseases</i> , 2021, 224, 657-666.	4.0	3
7	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 70, 1176-1185.	5.8	27
8	Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. <i>Aids</i> , 2020, 34, 2051-2059.	2.2	16
9	Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. <i>BMJ Open</i> , 2020, 10, e031487.	1.9	4
10	Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008â€“2015. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 170-177.	3.1	15
11	The PROSPER-HIV Study: A Research Protocol to Examine Relationships Among Physical Activity, Diet Intake, and Symptoms in Adults Living With HIV. <i>Journal of the Association of Nurses in AIDS Care</i> , 2020, 31, 346-352.	1.0	8
12	"Inflammascent" CX3CR1+CD57+ CD8 T cells are generated and expanded by IL-15. <i>JCI Insight</i> , 2020, 5, .	5.0	18
13	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV</i> , the, 2019, 6, e240-e249.	4.7	46
14	Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virusâ€“Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz100.	0.9	15
15	Stability of plasma indices of inflammation/coagulation and homeostasis after fatty and non-fatty meals in treated people with HIV. <i>Journal of Virus Eradication</i> , 2019, 5, 28-32.	0.5	0
16	Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 572-577.	2.1	12
17	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. <i>Clinical Infectious Diseases</i> , 2019, 68, 795-802.	5.8	13
18	Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort. <i>AIDS and Behavior</i> , 2019, 23, 627-635.	2.7	21

#	ARTICLE	IF	CITATIONS
19	Stability of plasma indices of inflammation/coagulation and homeostasis after fatty and non-fatty meals in treated people with HIV. <i>Journal of Virus Eradication</i> , 2019, 5, 28-32.	0.5	0
20	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 1230-1238.	5.8	131
21	Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. <i>Vaccine</i> , 2018, 36, 453-460.	3.8	19
22	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2018, 218, 239-248.	4.0	29
23	Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United States. <i>AIDS and Behavior</i> , 2018, 22, 742-751.	2.7	30
24	Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 916-921.	1.1	2
25	HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015. <i>Annals of Internal Medicine</i> , 2018, 169, 376.	3.9	91
26	Cycling CD4+ T cells in HIV-infected immune nonresponders have mitochondrial dysfunction. <i>Journal of Clinical Investigation</i> , 2018, 128, 5083-5094.	8.2	67
27	Lymphoid tissue fibrosis is associated with impaired vaccine responses. <i>Journal of Clinical Investigation</i> , 2018, 128, 2763-2773.	8.2	55
28	Identifying HIV care enrollees at-risk for cannabis use disorder. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 846-850.	1.2	12
29	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	5.8	44
30	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017, 65, 636-643.	5.8	67
31	Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. <i>AIDS Research and Therapy</i> , 2017, 14, 15.	1.7	9
32	Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. <i>AIDS and Behavior</i> , 2017, 21, 1138-1148.	2.7	145
33	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	8.4	104
34	Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. <i>Pathogens and Immunity</i> , 2017, 2, 151.	3.1	3
35	Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV. <i>Pathogens and Immunity</i> , 2017, 2, 376.	3.1	36
36	IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. <i>Journal of Clinical Investigation</i> , 2016, 126, 2745-2756.	8.2	97

#	ARTICLE	IF	CITATIONS
37	Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 437-443.	2.1	43
38	During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy. <i>Journal of Infectious Diseases</i> , 2016, 214, 1438-1448.	4.0	33
39	Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 483-492.	2.1	59
40	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	1.9	43
41	CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 392-396.	5.8	114
42	Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 154-160.	2.1	85
43	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	5.8	142
44	Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2014, 210, 1228-1238.	4.0	395
45	HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2014, 58, 1599-1606.	5.8	39
46	Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2014, 210, 1248-1259.	4.0	464
47	Current Practices of Screening for Incident Hepatitis C Virus (HCV) Infection Among HIV-Infected, HCV-Uninfected Individuals in Primary Care. <i>Clinical Infectious Diseases</i> , 2014, 59, 1686-1693.	5.8	19
48	Natural Cytotoxicity Receptor-Dependent Natural Killer Cytolytic activity Directed at Hepatitis C Virus (HCV) Is Associated With Liver Inflammation, African American Race, IL28B Genotype, and Response to Pegylated Interferon/Ribavirin Therapy in Chronic HCV Infection. <i>Journal of Infectious Diseases</i> , 2014, 209, 1591-1601.	4.0	8
49	Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. <i>Lancet HIV</i> , 2014, 1, e60-e67.	4.7	51
50	Identification of Occult <i>Fusobacterium nucleatum</i> Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3462-3464.	3.9	9
51	Inflammatory Cytokines Drive CD4+ T-Cell Cycling and Impaired Responsiveness to Interleukin 7: Implications for Immune Failure in HIV Disease. <i>Journal of Infectious Diseases</i> , 2014, 210, 619-629.	4.0	77
52	Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort. <i>Clinical Infectious Diseases</i> , 2014, 59, 279-286.	5.8	35
53	Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 96-101.	2.1	23
54	African Ancestry Influences CCR5 $\Delta 32$ Genotype-Associated Virologic Success of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 102-107.	2.1	6

#	ARTICLE	IF	CITATIONS
55	Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 756-764.	5.8	107
56	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2013, 208, 1240-1249.	4.0	43
57	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	5.8	90
58	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. <i>Blood</i> , 2013, 121, 4635-4646.	1.4	117
59	Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1221-1229.	6.3	152
60	Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. <i>Blood</i> , 2013, 121, 2914-2922.	1.4	31
61	Association of early HIV viremia with mortality after HIV-associated lymphoma. <i>Aids</i> , 2013, 27, 2365-2373.	2.2	33
62	Plasma Proteome Analysis Reveals Overlapping, yet Distinct Mechanisms of Immune Activation in Chronic HCV and HIV Infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 563-571.	2.1	15
63	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 149-163.	2.1	188
64	Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. <i>Aids</i> , 2013, 27, 1899-1909.	2.2	33
65	Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 351-359.	2.1	52
66	High Levels of Antiretroviral Use and Viral Suppression Among Persons in HIV Care in the United States, 2010. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 299-306.	2.1	51
67	Interferon- $\gamma$ Is the Primary Plasma Type-I IFN in HIV-1 Infection and Correlates with Immune Activation and Disease Markers. <i>PLoS ONE</i> , 2013, 8, e56527.	2.5	146
68	Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001-2009. <i>PLoS ONE</i> , 2013, 8, e78952.	2.5	9
69	Effect of Nadir CD4+ T Cell Count on Clinical Measures of Periodontal Disease in HIV+ Adults before and during Immune Reconstitution on HAART. <i>PLoS ONE</i> , 2013, 8, e76986.	2.5	13
70	Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. <i>PLoS ONE</i> , 2013, 8, e83514.	2.5	45
71	HIV Pathogenesis: The Host. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007005-a007005.	6.2	63
72	Baseline Levels of Soluble CD14 and CD16+56 $\gamma$ Natural Killer Cells Are Negatively Associated With Response to Interferon/Ribavirin Therapy During HCV-HIV-1 Coinfection. <i>Journal of Infectious Diseases</i> , 2012, 206, 969-973.	4.0	16

#	ARTICLE	IF	CITATIONS
73	Characterizing HIV Transmission Networks Across the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, 1135-1143.	5.8	120
74	Disseminated <i>Mycobacterium chelonae</i> Infection in a Patient Receiving an Epidermal Growth Factor Receptor Inhibitor for Advanced Head and Neck Cancer. <i>Journal of Clinical Microbiology</i> , 2012, 50, 194-195.	3.9	12
75	Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study. <i>Clinical Infectious Diseases</i> , 2012, 55, 291-300.	5.8	209
76	Bacterial Colonization and Beta Defensins in the Female Genital Tract in HIV Infection. <i>Current HIV Research</i> , 2012, 10, 504-512.	0.5	15
77	Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. <i>Clinical Infectious Diseases</i> , 2012, 54, 1026-1034.	5.8	453
78	Genetically Associated CD16+56 <sup>+</sup> Natural Killer Cell Interferon (IFN) $\gamma$ Expression Regulates Signaling and Is Implicated in IFN- $\gamma$ -Induced Hepatitis C Virus Decline. <i>Journal of Infectious Diseases</i> , 2012, 205, 1131-1141.	4.0	8
79	Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. <i>Aids</i> , 2012, 26, 1907-1915.	2.2	111
80	Increased Platelet and Microparticle Activation in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 340-346.	2.1	131
81	HIV-1 Is Not a Major Driver of Increased Plasma IL-6 Levels in Chronic HIV-1 Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 145-152.	2.1	30
82	Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. <i>Blood</i> , 2012, 120, 4599-4608.	1.4	188
83	Can immune-related genotypes illuminate the immunopathogenesis of cytomegalovirus disease in human immunodeficiency virus-infected patients?. <i>Human Immunology</i> , 2012, 73, 168-174.	2.4	8
84	Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT. <i>Cells</i> , 2012, 1, 127-140.	4.1	21
85	Genetic variations in loci relevant to natural killer cell function are affected by ethnicity but are generally not correlated with susceptibility to HIV-1. <i>Tissue Antigens</i> , 2012, 79, 367-371.	1.0	7
86	Interferon-Alpha Administration Enhances CD8+ T Cell Activation in HIV Infection. <i>PLoS ONE</i> , 2012, 7, e30306.	2.5	42
87	A Prospective Cohort Study of Periodontal Disease Measures and Cardiovascular Disease Markers in HIV-Infected Adults. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1157-1166.	1.1	16
88	Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load. <i>PLoS ONE</i> , 2011, 6, e21189.	2.5	28
89	Systemic Immune Activation in HIV Infection Is Associated with Decreased MDC Responsiveness to TLR Ligand and Inability to Activate Naive CD4 T-Cells. <i>PLoS ONE</i> , 2011, 6, e23884.	2.5	23
90	Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. <i>Aids</i> , 2011, 25, 185-195.	2.2	81

#	ARTICLE	IF	CITATIONS
91	Frequencies of FoxP3+ na <sup>+</sup> ve T cells are related to both viral load and na <sup>+</sup> ve T cell proliferation responses in HIV disease. <i>Journal of Leukocyte Biology</i> , 2011, 90, 621-628.	3.3	4
92	Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3 <sup>+</sup> Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3729-3742.	3.2	23
93	Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 635-645.	4.0	49
94	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. <i>American Journal of Epidemiology</i> , 2011, 174, 727-735.	3.4	9
95	Chemokine (C-C Motif) Receptor 5 <sup>+</sup> 2459 Genotype in Patients Receiving Highly Active Antiretroviral Therapy: Race-Specific Influence on Virologic Success. <i>Journal of Infectious Diseases</i> , 2011, 204, 291-298.	4.0	10
96	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	4.0	33
97	Immunologic Failure Despite Suppressive Antiretroviral Therapy Is Related to Activation and Turnover of Memory CD4 Cells. <i>Journal of Infectious Diseases</i> , 2011, 204, 1217-1226.	4.0	265
98	Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. <i>Blood</i> , 2010, 115, 161-167.	1.4	241
99	In vitro na <sup>+</sup> ve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection. <i>Clinical Immunology</i> , 2010, 136, 400-408.	3.2	8
100	Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations. <i>Infection, Genetics and Evolution</i> , 2010, 10, 60-67.	2.3	6
101	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , 2010, 7, 45.	1.7	73
102	Determinants of Protection among HIV <sup>+</sup> Exposed Seronegative Persons: An Overview. <i>Journal of Infectious Diseases</i> , 2010, 202, S333-S338.	4.0	49
103	Pretreatment Levels of Soluble Cellular Receptors and Interleukin <sup>+</sup> 6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 1796-1805.	4.0	124
104	Peripheral Blood B Cell Subset Skewing Is Associated with Altered Cell Cycling and Intrinsic Resistance to Apoptosis and Reflects a State of Immune Activation in Chronic Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2010, 185, 3019-3027.	0.8	52
105	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2010, 50, 1512-1520.	5.8	187
106	Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control. <i>PLoS Pathogens</i> , 2010, 6, e1000917.	4.7	284
107	Differential Effects of Hepatitis C Virus JFH1 on Human Myeloid and Plasmacytoid Dendritic Cells. <i>Journal of Virology</i> , 2009, 83, 5693-5707.	3.4	29
108	Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral <sup>+</sup> treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 1177-1185.	4.0	527



#	ARTICLE	IF	CITATIONS
109	Incomplete Peripheral CD4 <sup>+</sup> Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2009, 48, 787-794.	5.8	329
110	Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. <i>Aids</i> , 2009, 23, 1359-1366.	2.2	305
111	Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384. <i>Clinical Infectious Diseases</i> , 2009, 48, 350-361.	5.8	202
112	Impaired Plasmacytoid Dendritic Cell (PDC)-NK Cell Activity in Viremic Human Immunodeficiency Virus Infection Attributable to Impairments in both PDC and NK Cell Function. <i>Journal of Virology</i> , 2009, 83, 11175-11187.	3.4	37
113	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. <i>Clinical Infectious Diseases</i> , 2009, 49, 1582-1590.	5.8	55
114	Accessory cell dependent NK cell mediated PBMC IFN- $\beta$ production is defective in HIV infection. <i>Clinical Immunology</i> , 2009, 131, 288-297.	3.2	9
115	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. <i>New England Journal of Medicine</i> , 2009, 360, 1815-1826.	27.0	986
116	S03-06 OA. Rapid perforin upregulation by CD8 T cells in elite controllers as a correlate of immune-mediated control of HIV replication. <i>Retrovirology</i> , 2009, 6, .	2.0	0
117	Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. <i>Blood</i> , 2009, 113, 5497-5505.	1.4	41
118	Impaired Naive and Memory B-Cell Responsiveness to TLR9 Stimulation in Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2008, 82, 7837-7845.	3.4	34
119	Hepatitis C Virus-Specific T-Cell Gamma Interferon and Proliferative Responses Are More Common in Perihepatic Lymph Nodes than in Peripheral Blood or Liver. <i>Journal of Virology</i> , 2008, 82, 11742-11748.	3.4	7
120	Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV. <i>HIV Clinical Trials</i> , 2008, 9, 91-102.	2.0	12
121	Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. <i>International Journal of Epidemiology</i> , 2008, 37, 948-955.	1.9	242
122	Increased Levels of Human Beta-Defensins mRNA in Sexually HIV-1 Exposed But Uninfected Individuals. <i>Current HIV Research</i> , 2008, 6, 531-538.	0.5	74
123	Toll-Like Receptor Ligands Induce Human T Cell Activation and Death, a Model for HIV Pathogenesis. <i>PLoS ONE</i> , 2008, 3, e1915.	2.5	120
124	HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211. <i>Clinical Infectious Diseases</i> , 2007, 44, 591-595.	5.8	179
125	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , 2007, 36, 294-301.	1.9	176
126	Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 805.	7.4	0



#	ARTICLE	IF	CITATIONS
127	Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART. <i>Journal of the International Association of Providers of AIDS Care</i> , 2007, 6, 198-202.	1.2	13
128	Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. <i>Blood</i> , 2007, 109, 4272-4279.	1.4	175
129	Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 56-61.	3.8	9
130	TLR Ligand-Dependent Activation of Naive CD4 T Cells by Plasmacytoid Dendritic Cells Is Impaired in Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2007, 178, 4436-4444.	0.8	69
131	TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function. <i>European Journal of Immunology</i> , 2007, 37, 2205-2213.	2.9	132
132	Gender differences in human immunodeficiency virus (HIV) RNA and CD4 cell counts among new entrants to HIV care. <i>Clinical Microbiology and Infection</i> , 2006, 12, 389-391.	6.0	14
133	Microbial translocation is a cause of systemic immune activation in chronic HIV infection. <i>Nature Medicine</i> , 2006, 12, 1365-1371.	30.7	3,107
134	Interferon- $\gamma$ differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. <i>Aids</i> , 2006, 20, 1379-1389.	2.2	34
135	Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 426-434.	2.1	148
136	Predictive Value of Plasma HIV RNA Level on Rate of CD4 T-Cell Decline in Untreated HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1498.	7.4	288
137	Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138. <i>Journal of Infectious Diseases</i> , 2006, 194, 1677-1685.	4.0	39
138	HIV Coinfection Impairs CD28-Mediated Costimulation of Hepatitis C Virus-Specific CD8 Cells. <i>Journal of Infectious Diseases</i> , 2006, 194, 391-400.	4.0	15
139	Persistent Replication of Human Immunodeficiency Virus Type 1 despite Treatment of Pulmonary Tuberculosis in Dually Infected Subjects. <i>Vaccine Journal</i> , 2005, 12, 1298-1304.	3.1	20
140	New Entrants to HIV Care Are Presenting Only at Marginally Earlier Stages of Disease but May Increasingly Represent Groups Perceived at Lower Risk. <i>Journal of the International Association of Providers of AIDS Care</i> , 2005, 4, 47-51.	1.2	2
141	Impaired Monocyte Maturation in Response to CpG Oligodeoxynucleotide Is Related to Viral RNA Levels in Human Immunodeficiency Virus Disease and Is at Least Partially Mediated by Deficiencies in Alpha/Beta Interferon Responsiveness and Production. <i>Journal of Virology</i> , 2005, 79, 4109-4119.	3.4	37
142	Peripheral S $\alpha$ -Phase T Cells in HIV Disease Have a Central Memory Phenotype and Rarely Have Evidence of Recent T Cell Receptor Engagement. <i>Journal of Infectious Diseases</i> , 2005, 192, 62-70.	4.0	42
143	Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5. <i>Science</i> , 2004, 306, 485-487.	12.6	364
144	Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virus-Infected Patients. <i>Journal of Infectious Diseases</i> , 2003, 187, 504-507.	4.0	38

#	ARTICLE	IF	CITATIONS
145	Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. <i>Aids</i> , 2003, 17, 1983-1985.	2.2	46
146	Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. <i>Aids</i> , 2003, 17, 1907-1915.	2.2	229
147	A Family Cluster of Five Cases of Group A Streptococcal Pneumonia. <i>Pediatrics</i> , 2003, 112, e61-e65.	2.1	22